Mitchell E. Gross, MD, PhD

Associate Professor of Clinical Medicine

Image of Mitchell E. Gross, MD, PhD
Is this your profile? Click to edit


Dr. Gross is research director of the USC Norris Westside Cancer Center and the Center for Applied Molecular Medicine. His overall research interest focuses on applying modern techniques relating to the study of genes and proteins (genomics and proteomics) on the clinical problems faced in treating patients with prostate cancer. A particular interest relates to the androgen receptor and relating proteins and pathways as key driving forces behind the development and treatment of prostate cancer. As a medical oncologist, his clinical activities are focused on therapeutic clinical trials incorporating both molecularly targeted and conventional therapies to the care of patients with prostate cancer. He serves as primary investigator on many multi-center phase 1 and 2 clinical trials

Dr. Gross has earned degrees from the University of California, San Diego (B.A.), Baylor College of Medicine in Houston (M.D.), and the University of California, Los Angeles (Ph.D. Molecular Biology). He completed a residency in internal medicine and a fellowship in hematology and medical oncology at the UCLA Center for the Health Sciences.


  • Donna and Jesse Garber Award, 2006
  • AACR-AFLAC Scholar in Training Award,, 2001
  • Amgen Fellowship Research Award, 1999
  • Rhone Phoulenc Rorer Travel Award, 1999
  • Specialty Training Advanced Research Fellowship, 1997-2002
  • Hewlett Packard Award for Excellence in Internal Medicine, 1994
  • Alpha Omega Alpha, 1994
  • UCSD/Revelle College Academic: Leadership Award, 1990
  • Phi Beta Kappa, 1989


  • MRI Detection of Lymph Node Metastasis through Molecular Targeting of C-C Chemokine Receptor Type 2 and Monocyte Hitchhiking ACS Nano. 2024 Jan 23; 18(3):2091-2104. . View in PubMed
  • Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics Cancers (Basel). 2023 Aug 03; 15(15). . View in PubMed
  • Immune biomarkers associated with COVID-19 disease severity in an urban, hospitalized population Pract Lab Med. 2023 Aug; 36:e00323. . View in PubMed
  • Synthesis and anti-cancer potential of potent peripheral MAOA inhibitors designed to limit blood:brain penetration Bioorg Med Chem. 2023 09 07; 92:117425. . View in PubMed
  • Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer Prostate Cancer Prostatic Dis. 2021 03; 24(1):61-68. . View in PubMed
  • In Vivo Non-Thermal, Selective Cancer Treatment With High-Frequency Medium-Intensity Focused Ultrasound IEEE Access. 2021; 9:122051-122066. . View in PubMed
  • Effect of Periodized Resistance Training on Skeletal Muscle During Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Trial Integr Cancer Ther. 2021 Jan-Dec; 20:15347354211035442. . View in PubMed
  • CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation J Control Release. 2021 01 10; 329:614-623. . View in PubMed
  • Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA) BMC Res Notes. 2019 May 15; 12(1):275. . View in PubMed
  • Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)Clin Genitourin Cancer. 2019 08; 17(4):241-247. e1. . View in PubMed
  • Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells Prostate. 2019 05; 79(6):667-677. . View in PubMed
  • Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis Oncogene. 2019 04; 38(16):3003-3018. . View in PubMed
  • Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2) Oncotarget. 2018 Jun 08; 9(44):27363-27379. . View in PubMed
  • Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate Oncogene. 2018 09; 37(38):5175-5190. . View in PubMed
  • Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial BMC Cancer. 2018 04 03; 18(1):368. . View in PubMed
  • Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles ACS Biomater Sci Eng. 2017 Dec 11; 3(12):3273-3282. . View in PubMed
  • Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC) Clin Genitourin Cancer. 2017 Jul 14. . View in PubMed
  • A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy BMJ Open. 2017 Jul 10; 7(7):e016910. . View in PubMed
  • Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells Endocr Relat Cancer. 2017 04; 24(4):157-170. . View in PubMed
  • Automated analysis of co-localized protein expression in histologic sections of prostate cancer PLoS One. 2017; 12(5):e0178362. . View in PubMed
  • A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients Prostate Cancer Prostatic Dis. 2016 12; 19(4):323-332. . View in PubMed
  • Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial designUrol Oncol. 2015 Nov; 33(11):495. e1-7. . View in PubMed
  • Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies World J Urol. 2015 Nov; 33(11):1669-76. . View in PubMed
  • Blood-based gene expression profiling in castrate-resistant prostate cancer BMC Med. 2015 Sep 14; 13:219. . View in PubMed
  • A novel technique using three-dimensionally documented biopsy mapping allows precise re-visiting of prostate cancer foci with serial surveillance of cell cycle progression gene panel Prostate. 2015 Jun; 75(8):863-71. . View in PubMed
  • Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors Psychooncology. 2015 Feb; 24(2):228-35. . View in PubMed
  • Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer? Am Soc Clin Oncol Educ Book. 2015; e270-3.. View in PubMed
  • Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression PLoS One. 2015; 10(2):e0117758. . View in PubMed
  • A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. . View in PubMed
  • Phase I/II trial of orteronel (TAK-700)–an investigational 17,20-lyase inhibitor–in patients with metastatic castration-resistant prostate cancer Clin Cancer Res. 2014 Mar 01; 20(5):1335-44. . View in PubMed
  • Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells PLoS One. 2014; 9(8):e101777. . View in PubMed
  • Body image predicts quality of life in men with prostate cancer Psychooncology. 2013 Apr; 22(4):756-61. . View in PubMed
  • Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype Prostate. 2013 Feb 15; 73(3):306-15. . View in PubMed
  • Prostate cancer: Age is nothing but a number Nat Rev Urol. 2013 12; 10(12):683-4. . View in PubMed
  • Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer Clin Genitourin Cancer. 2012 Dec; 10(4):232-8. . View in PubMed
  • Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer Clin Nucl Med. 2012 Jul; 37(7):637-43. . View in PubMed
  • Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 37 years. Eur Urol. 2012 Jul; 62(1):55-63. . View in PubMed
  • Multimodality imaging in biochemical recurrence of prostate cancer: utility of (18)F-NaF PET/CT in early detection of metastasis Rev Esp Med Nucl Imagen Mol. 2012 Jul-Aug; 31(4):231-2. . View in PubMed
  • Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition Mol Cancer Ther. 2012 May; 11(5):1071-81. . View in PubMed
  • 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion J Urol. 2012 Mar; 187(3):1080-6. . View in PubMed
  • Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line Phys Biol. 2012 Feb; 9(1):016002. . View in PubMed
  • Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80. . View in PubMed
  • Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium Invest New Drugs. 2011 Dec; 29(6):1432-40. . View in PubMed
  • Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer Urology. 2011 May; 77(5):1166-71. . View in PubMed
  • Show us a sign: the search for “game changing” prostate cancer biomarkers Lancet Oncol. 2011 Mar; 12(3):204-6. . View in PubMed
  • The epothilones: new therapeutic agents for castration-resistant prostate cancer Oncologist. 2011; 16(10):1349-58. . View in PubMed
  • Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer Clin Chem. 2010 Sep; 56(9):1492-5. . View in PubMed
  • Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling Prostate. 2010 Aug; 70(11):1201-10. . View in PubMed
  • Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping Psychooncology. 2009 May; 18(5):508-14. . View in PubMed
  • Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene Leuk Res. 2007 Jan; 31(1):27-32. . View in PubMed
  • Ductal adenocarcinoma of the prostate Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5; discussion 396. . View in PubMed
  • Targeting the HER-kinase axis in cancer Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20. . View in PubMed
  • Update on HER-kinase-directed therapy in prostate cancer Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-664. . View in PubMed